CRISPR THERAPEUTICS AG Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
CRISPR THERAPEUTICS AG (CRSP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -0.40% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-12
- CRISPR THERAPEUTICS AG effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -0.40%.
- CRISPR THERAPEUTICS AG effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -4.00%.
- CRISPR THERAPEUTICS AG effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.20%.
- CRISPR THERAPEUTICS AG effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was -2.50%, a 208.70% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2024-12-31 | -0.40% 10-K · filed 2026-02-12 |
| 2023-12-31 | -4.00% 10-K · filed 2026-02-12 |
| 2022-12-31 | -0.20% 10-K · filed 2025-02-11 |
| 2021-12-31 | -2.50% 10-K · filed 2024-02-21 |
| 2020-12-31 | 2.30% 10-K · filed 2023-02-21 |
| 2019-12-31 | -2.00% 10-K · filed 2022-02-15 |
| 2018-12-31 | 1.40% 10-K · filed 2021-02-16 |
| 2017-12-31 | -2.90% 10-K · filed 2020-02-12 |
| 2016-12-31 | -4.90% 10-K · filed 2019-02-25 |
| 2015-12-31 | -1.40% 10-K · filed 2018-03-08 |
| 2014-12-31 | -1.10% 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |